ClinicalTrials.gg
RecruitingNCT06786572ITEMUpdated Feb 2, 2026

Interoceptive Training Enhanced Mindfulness

An interventional study of Mindfulness training and Interoceptive exposure in Anxiety Sensitivity, sponsored by Veterans Medical Research Foundation. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Veterans Medical Research Foundation · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This pilot randomized controlled trial will compare a novel mindfulness training to interoceptive exposure to establish feasibility and acceptability as an intervention for anxiety sensitivity.

Read the detailed description

Anxiety sensitivity (AS), which involves fear that arousal related symptoms will have negative physical, social or psychological ramifications, is an important driver of anxiety, trauma-related and somatic disorders. Cognitive behavioral therapy (CBT), particularly involving interoceptive exposure (IE; i.e., exposure to unwanted internal sensations), has the greatest demonstrated efficacy at reducing AS but can be hard to tolerate. Conversely, mindfulness is sought out for management of multiple mental health problems, but the observed clinical effects are often modest. A hybrid of these two approaches may capitalize on the strengths of each approach. Mindfulness training (MT) may increase the tolerability of exposure, enhance compliance and support extinction learning through increased engagement with the feared stimulus and heightened awareness of the nonoccurrence of feared outcomes. This project will evaluate the feasibility and acceptability of a novel hybrid intervention, Interoceptive Training Enhanced Mindfulness (ITEM), which combines IE with MT, evaluate its feasibility and acceptability. Forty-eight Veterans will be randomized to receive ITEM or IE in six one-on-one sessions delivered via telehealth. They will complete assessments before and after the 6-week intervention period. Outcomes related to engagement and compliance with ITEM and IE will be the primary focus. Because multiple mental health (e.g., anxiety, posttraumatic stress disorder, eating disorders and depression) and physical health (e.g., chronic pain, conditions related to toxic exposure) problems are driven by maladaptive reactions to interoceptive cues, this intervention has the potential to ultimately produce wide-spread mental and physical health benefits.

02

Conditions studied

  • Anxiety Sensitivity

Keywords

  • anxiety sensitivity
  • mindfulness
  • interoception
03

In context

Lead sponsor

Veterans Medical Research Foundation is the lead sponsor of 43 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Veteran status
  • able to read and speak English
  • ASI-3 score of 23 or higher
  • distress/impairment related to an emotional or somatic complaint as determined by a Clinical Global Impression Scale (CGI) of 3 or greater
  • Internet access via a device that can support remote study activities and ability to attend in person appointments

Exclusion criteria

Exclusion Criteria:

  • serious mental illness, including bipolar disorder or psychotic illness
  • current, untreated alcohol or substance use disorder
  • moderate-severe suicidality that would likely result in the need for urgent intervention in the next 2 months
  • current regular meditation practice or treatment for AS-related condition
  • cognitive dysfunction that interferes with the ability to engage in treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Interoceptive Training Enhanced Mindfulness (ITEM)

    Brief mindfulness training focused on management of unwanted internal sensations

    Other: Mindfulness training

  • Active comparator
    Interoceptive Exposure (IE)

    Cognitive behavioral intervention featuring systematic exposure to unwanted internal sensations

    Behavioral: Interoceptive exposure

Interventions

  • OtherMindfulness training

    Brief mindfulness training focused on management of unwanted internal sensations

  • BehavioralInteroceptive exposure

    Cognitive behavioral therapy focused in interoceptive exposure to unwanted internal sensations

06

What researchers measure

Primary outcomes

  1. Enrollment rate

    Number enrolled out of number approached

    Time frame: Typically up to 3 months, from initial referral to decision to enroll or not

  2. Attendance

    Average number of sessions attended

    Time frame: During the six-week intervention period

  3. Clinician's judgment of proportion of completion of at home assignments

    Clinician's judgment of proportion of completion of at home assignments on a scale including none, partial and complete

    Time frame: During the six-week intervention period

  4. Client Satisfaction Questionnaire-4 (CSQ-4)

    The CSQ-4 is a validated measure of participant satisfaction with care delivered with higher scores (range 4-16) indicating greater satisfaction.

    Time frame: Week 6, following the final treatment session

  5. Reliable change

    Proportion improved, unchanged and worsened based on the Reliable Change Index using the Overall Anxiety Symptoms and Impairment Scale (OASIS).

    Time frame: Over a 6-8 week period from baseline to post-treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Final datasets in machine-readable format will be shared via PubMed Central

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Available 3/31/28, indefinite

Access criteria: Public access

Data sharing details ↗ · pmc.ncbi.nlm.nih.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Mar 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2025
First posted
Jan 22, 2025
StartActual
Sep 10, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06786572
Lead sponsor
Veterans Medical Research Foundation
Responsible party
Sponsor
First posted
Jan 22, 2025
Start date
Sep 10, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Feb 2, 2026

Study contacts

Ariel J Lang, PhD, MPH
Contact
ariel.lang@va.gov
8585528585 ext. x5359
Jafer Vazquez Alcaraz
Contact
jafer.vazquezalcaraz@va.gov
858-367-0243

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion